XSurgical Robotics by XSurgical

XSurgical Robotics by XSurgical

We move the technology, not the patients

Security Type
Preferred Stock
Min Investment
Cambridge, MA
Offering Date
December 16, 2021
Expected Close Date
March 22, 2022
Target Raise
Security Price

Company Description

XSurgical plans to take to market what Management believes to be the first surgical robot capable of both operating in hospitals and portable in the open field, integrating minimally invasive, open surgery and orthopedic procedures.

Key Deal Facts

XSurgical is creating an entirely new market segment through the novel paradigm developing a robot capable of performing a wide variety of procedures reaching a bigger number of hospitals and open field applications.
We are aiming to serve about 3% of a $15 Billion market. Approximately $6 million of funding deployed into our company to date.
We believe XSurgical’s Robot is unique in that it is designed to be the first Open Architecture Surgical Robot, enabling third parties to implement their tools and procedures for our platform.

Management Team / Advisory Board Bios

Gianluca De Novi
Founder & Chief Executive Officer
Gianluca De Novi, Ph.D. A faculty member at the Harvard Medical School and Harvard Extension School, he earned his master's degree in Electronics Engineering and his Ph.D. in robotics and control systems from the University of Bologna in Italy. While there, he also worked as researcher at the Laboratory of Automation and Robotics, the Computer Vision Laboratory and the Microelectronics Laboratory. After spending one year as a visiting researcher at the Bio-Robotics Laboratory of Harvard's School of Engineering and Applied Sciences, he completed his Postdoctoral fellowship in Medical Device Design and Medical Simulation at the Department of Imaging at the Massachusetts General Hospital (now Massachusetts General Brigham) and became a Harvard Medical School faculty in Boston, MA. Dr. De Novi has also acted as scientific consultant to many leading corporations and research institutions. His interest in computer-based surgery began with exploration of cutting-edge technologies for graphic rendering and developing a complete virtual reality framework optimized for haptic rendering and surgical robotics. During his post-doctoral fellowship, he focused his interests on other crucial aspects of robotic surgery, such as real-time gesture analysis and task recognition, Human Machine Interaction and Augmented Reality. Through his academic position he has lead and participated to many important DoD funded research in this domain and contributed in the definition of upcoming standards in the Med-Tech field. He has been a scientific and strategic advisor at ADM Tronics Unlimited Inc. since May 2015 and served as a member of its Advisory Board since September 2014. Dr. De Novi is currently Chief Technical Officer (after a fast transition from an advisory appointment) at Plymouth Rock Technology, leading the development of Threat Detection technologies since February 2021, one more time developing technologies of interest for the US government. Among the many recognition that Dr. De Novi received during his career, stands out the PrimiDieci Society and the Italy-America Chamber of Commerce recognition of Dr. De Novi as one of the Top Ten most distinguished Italian Professionals in the United States under the age of 40 in 2013. Gianluca De Novi resides in Massachusetts.

Michele Marzola
Founder & Chairman of the Board
Michele Marzola is a serial entrepreneur with experience in more than 20 start-ups in Life Sciences that he founded and funded during the past 12 years. His experience ranges from medical devices to biotech. He was Chairman and President at Angiodroid, a company that he took to market leadership in peripheral angiographies through an innovative technology using Carbon Dioxide as contrast medium. Angiodroid consistently delivered triple digit growth under Michele's leadership and was already profitable after three years from funding. At Green Bone Ortho Michele led a group of private investors to complete one of the largest Seed rounds in Italy and then led the Series A and Series B rounds for an aggregate value of 30 M; Green Bone is now demonstrating its capability to regenerate bone even on large missing sections of several centimeters. At Interceptin Michele has co-founded a company developing a very promising therapy for prostate cancer and other solid tumors, based on an immunotoxin driven by a bispecific antibody fragment. At Surgica Robotica Michele led the company from its inception, achieving funding and development of the two first successful prototypes. Michele was previously General Manager at IBM, with responsibility of its consulting and application management services in Europe, Middle East and Africa; at IBM Michele also negotiated a JV with Enel S.p.A. and spearheaded the creation of intelligent networks around the globe. Mr. Marzola has an MBA with top honors from Columbia University in New York and an MSc in Mechanical Engineering with full grades from the University of Bologna in Italy. Michele Marzola resides in Italy.

Debora Botturi
Founder & Chief Scientific Officer
Dr. Debora Botturi, PhD, is an Executive with experience in innovation and technology transfer. Her experience is on Innovation and Communication Technologies (ICT) and her focus is on the application domain of robotic surgery. She received a masters degree in Computer Science and a Ph.D. in Computer Science from the University of Verona with a specialization in teleoperation systems and automatic execution of robotic tasks. She was a post-doc at Dept. of Robotic and Mechatronic, DLR, Munich, Germany, and she was project manager of a ground breaking European Project on robotic surgery. Since 2013 she is an Innovation Manager carrying out research and supervision of industrial projects in the areas of robotics and advanced sensors and also an expert evaluator for the European Commission. Debora Botturi resides in Italy.
Amount Raised : $26,781
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

Preferred securities are a type of investment that generally offers some sort of preferred treatment through a dividend or preferred treatment in a liquidation.

Research Reports

No reports have been submitted

Become a Reporter